C. Vermylen

1.7k total citations
45 papers, 1.2k citations indexed

About

C. Vermylen is a scholar working on Hematology, Epidemiology and Hepatology. According to data from OpenAlex, C. Vermylen has authored 45 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hematology, 11 papers in Epidemiology and 8 papers in Hepatology. Recurrent topics in C. Vermylen's work include Hepatitis B Virus Studies (7 papers), Hepatitis C virus research (7 papers) and Hemophilia Treatment and Research (6 papers). C. Vermylen is often cited by papers focused on Hepatitis B Virus Studies (7 papers), Hepatitis C virus research (7 papers) and Hemophilia Treatment and Research (6 papers). C. Vermylen collaborates with scholars based in Belgium, Switzerland and Germany. C. Vermylen's co-authors include H. Claeys, Marc Verstraete, M Verstraete, Alfons Billiau, Marc De Ley, J Vandenbroucke, J. Vermylen, A Amery, Piet De Somer and J. Vermylen and has published in prestigious journals such as The Lancet, Neurology and The American Journal of Medicine.

In The Last Decade

C. Vermylen

43 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
C. Vermylen Belgium	18	339	248	227	203	202	45	1.2k
Shmuel Gillis Israel	19	532 1.6×	195 0.8×	131 0.6×	87 0.4×	121 0.6×	44	1.1k
Ronald A. Yankee United States	23	738 2.2×	181 0.7×	88 0.4×	260 1.3×	84 0.4×	49	1.5k
Kiyoshi Kitano Japan	25	599 1.8×	191 0.8×	286 1.3×	483 2.4×	70 0.3×	92	1.7k
Juan C. Scornik United States	31	370 1.1×	270 1.1×	184 0.8×	572 2.8×	196 1.0×	81	2.4k
Jacob Nusbacher United States	22	483 1.4×	148 0.6×	68 0.3×	276 1.4×	108 0.5×	48	1.2k
William E. Beschorner United States	9	662 2.0×	176 0.7×	103 0.5×	126 0.6×	123 0.6×	11	1.1k
Hirobumi Kondo Japan	25	137 0.4×	282 1.1×	201 0.9×	404 2.0×	78 0.4×	85	1.7k
Andrew J. Woodroffe Australia	25	258 0.8×	90 0.4×	299 1.3×	445 2.2×	51 0.3×	61	1.7k
B. Kubanek Germany	25	1.2k 3.4×	276 1.1×	208 0.9×	396 2.0×	194 1.0×	138	2.1k
H. O. Nieweg Netherlands	19	209 0.6×	237 1.0×	135 0.6×	173 0.9×	53 0.3×	73	1.3k

Countries citing papers authored by C. Vermylen

Since Specialization

Citations

This map shows the geographic impact of C. Vermylen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Vermylen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Vermylen more than expected).

Fields of papers citing papers by C. Vermylen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Vermylen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Vermylen. The network helps show where C. Vermylen may publish in the future.

Co-authorship network of co-authors of C. Vermylen

This figure shows the co-authorship network connecting the top 25 collaborators of C. Vermylen. A scholar is included among the top collaborators of C. Vermylen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Vermylen. C. Vermylen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Gandemer, Virginie, Sylvie Chevret, Arnaud Petit, et al.. (2012). Excellent prognosis of late relapses of ETV6/RUNX1-positive childhood acute lymphoblastic leukemia: lessons from the FRALLE 93 protocol. Haematologica. 97(11). 1743–1750. 39 indexed citations

Lannoy, N., et al.. (2011). Computational and molecular approaches for predicting unreported causal missense mutations in Belgian patients with haemophilia A. Haemophilia. 18(3). e331–9. 10 indexed citations

Lê, Phu-Quoc, Alina Ferster, Frédéric Cotton, et al.. (2010). Sickle cell disease from Africa to Belgium, from neonatal screening to clinical management.. PubMed. 70(5-6). 467–70. 16 indexed citations

Lambert, Cameron T., et al.. (2006). Inadvertent anticoagulation of a haemophiliac child with routine line flushing. Haemophilia. 12(5). 548–550. 3 indexed citations

Bernard, Frédéric, Caroline Thomas, Y. Bertrand, et al.. (2005). Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction. European Journal of Cancer. 41(17). 2682–2689. 87 indexed citations

Emonds, Marie‐Paule, Sabine Scherer, Mark Waer, et al.. (1996). A single center evaluation of the Collaborative Transplant Study (CTS) DNA project. Transplant International. 9(5). 468–475. 2 indexed citations

Claeys, H., et al.. (1994). Evaluation of Third‐Generation Screening and Confirmatory Assays for HCV Antibodies. Vox Sanguinis. 66(2). 122–129. 110 indexed citations

Claeys, H., et al.. (1993). Hepatitis C Virus Confirmation in Blood Donor Screening. Vox Sanguinis. 64(3). 145–149. 16 indexed citations

Beenhouwer, Hans De, et al.. (1992). Confirmation of Hepatitis C Virus Positive Blood Donors by Immunoblotting and Polymerase Chain Reaction. Vox Sanguinis. 63(3). 198–203. 25 indexed citations

10.

Claeys, H., et al.. (1992). Association of hepatitis C virus carrier state with the occurrence of hepatitis C virus core antibodies. Journal of Medical Virology. 36(4). 259–264. 17 indexed citations

11.

Ketelaer, P, et al.. (1986). Transfer factor therapy in multiple sclerosis. Neurology. 36(10). 1399–1399. 3 indexed citations

12.

Claeys, H., Jo Van Damme, Marc De Ley, C. Vermylen, & Alfons Billiau. (1982). Activation of natural cytotoxicity of human peripheral blood mononuclear cells by interferon: a kinetic study and comparison of different interferon types. British Journal of Haematology. 50(1). 85–94. 29 indexed citations

13.

Billiau, Alfons, H. Claeys, Jo Van Damme, et al.. (1981). Interferon therapy in multiple myeloma: Failure of human fibroblast interferon administration to affect the course of light chain disease. European Journal of Cancer and Clinical Oncology. 17(8). 875–882. 8 indexed citations

14.

Vermylen, C., et al.. (1971). CHORIOCARCINOMA AND HL-A ANTIGENS. The Lancet. 298(7729). 874–874. 2 indexed citations

15.

Verstraete, M, et al.. (1964). Practical Method for Thrombolytic Therapy With Streptokinase. BMJ. 1(5384). 675–676. 5 indexed citations

16.

Verstraete, M, et al.. (1963). HEPARIN TREATMENT OF BLEEDING. The Lancet. 281(7278). 446–446. 28 indexed citations

17.

Vermylen, C., et al.. (1963). A rapid enzymatic method for assay of fibrinogen fibrin polymerization time (FPT test). Clinica Chimica Acta. 8(3). 418–424. 239 indexed citations

18.

Verstraete, Marc, C. Vermylen, & Jan P. Vandenbroucke. (1962). HEMOPHILIA B ASSOCIATED WITH A DECREASED FACTOR VII ACTIVITY. The American Journal of the Medical Sciences. 243(1). 20–26. 12 indexed citations

19.

Vermylen, C. & Marc Verstraete. (1961). Antithrombin V: Critical Evaluation of its Assessment and Properties. Thrombosis and Haemostasis. 5(2). 267–284. 24 indexed citations

20.

Vermylen, C., et al.. (1960). [Experimental studies on some problems of blood coagulation with reference to extracorporeal circulation].. PubMed. 2. 294–302. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact